CONCERTA Drug Patent Profile

When do Concerta patents expire, and when can generic versions of Concerta launch?

Concerta is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in CONCERTA is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Concerta

A generic version of CONCERTA was approved as methylphenidate hydrochloride by SPECGX LLC on November 27^th, 1998.

Summary for CONCERTA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	95
Patent Applications:	4,658
Drug Prices:	Drug price information for CONCERTA
Drug Sales Revenues:	Drug sales revenues for CONCERTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CONCERTA
What excipients (inactive ingredients) are in CONCERTA?	CONCERTA excipients list
DailyMed Link:	CONCERTA at DailyMed

See drug prices for CONCERTA

See drug sales revenues for CONCERTA

Recent Clinical Trials for CONCERTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	EARLY_PHASE1
Bazelet Nehushtan LtD.	PHASE2
Stéphanie Baggio	Phase 3

See all CONCERTA clinical trials

Pharmacology for CONCERTA

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for CONCERTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CONCERTA	Extended-release Tablets	methylphenidate hydrochloride	18 mg*, 27 mg, 36 mg and 54 mg	021121		2005-07-19

US Patents and Regulatory Information for CONCERTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	CONCERTA	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021121-001	Aug 1, 2000	AB	RX	Yes	No
Janssen Pharms	CONCERTA	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021121-003	Dec 8, 2000	AB	RX	Yes	Yes
Janssen Pharms	CONCERTA	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021121-004	Apr 1, 2002	AB	RX	Yes	No

Expired US Patents for CONCERTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	CONCERTA	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021121-004	Apr 1, 2002	6,919,373*PED
Janssen Pharms	CONCERTA	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021121-002	Aug 1, 2000	4,519,801
Janssen Pharms	CONCERTA	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021121-003	Dec 8, 2000	9,000,038*PED

International Patents for CONCERTA

See the table below for patents covering CONCERTA around the world.

Country	Patent Number	Title	Estimated Expiration
China	1182839
United Kingdom	2140687	OSMOTIC DRUG DELIVERY SYSTEM
Israel	140020	DOSAGE FORM FOR ACHIEVING AN ASCENDING PLASMA CONCENTRATION PROFILE FOLLOWING ADMINISTRATION FOR AN EXTENDED TIME PERIOD

Market Dynamics and Financial Trajectory for CONCERTA®

Last updated: January 14, 2026

Summary

CONCERTA® (methylphenidate extended-release) is a leading prescription medication primarily used for treating Attention Deficit Hyperactivity Disorder (ADHD) in both pediatric and adult populations. Launched in 2000, CONCERTA has established a significant presence within the stimulant therapy market. This report analyzes its current market position, underlying market dynamics, competitive landscape, and forecasted financial trajectory, considering regulatory, R&D, and market growth factors.

---

What are the key market drivers influencing CONCERTA's growth?

Market Drivers	Details
Rising prevalence of ADHD	Globally, ADHD diagnoses increased by over 15% from 2010-2022, driven by better awareness, diagnostic criteria expansion, and pediatric screening programs (CDC, 2022).
Expanding adult ADHD diagnosis	Adults now constitute nearly 50% of diagnosed cases, expanding market potential.
Patent expiration and generics	U.S. patent expired in 2017, opening markets for generic methylphenidate formulations, though CONCERTA retains brand strength through formulary inclusion and brand loyalty.
Increased adherence to medication	Dosing convenience and extended-release profiles lead to higher compliance rates, fueling sustained demand.
Reimbursement policies	Favorable insurance coverage and formulary placements bolster sales growth.

---

What is the competitive landscape?

Player/Brand	Type	Market Share (2022)	Strengths	Weaknesses
CONCERTA (Janssen)	Brand (Extended-release methylphenidate)	~45%	Strong brand equity, extensive clinician trust, favorable dosing profile	Premium pricing, patent expiry impact
Generic Methylphenidate ER	Generics	~40%	Cost-effective, widespread availability	Lower brand recognition, variable formulation quality
Other branded options	Strattera, Vyvanse	Remaining ~15%	Unique mechanisms (e.g., non-stimulant), alternative profiles	Smaller market share, distinct profile needs

Note: Exact market shares fluctuate annually and regionally; data reflects U.S. estimates from IQVIA (2022).

---

How do regulatory and policy factors impact CONCERTA?

Factor	Impact
FDA approval status	Fully approved; ongoing post-marketing surveillance supports market confidence.
Patent landscape	Patents expired in 2017, enabling generic competition, but Janssen maintains market exclusivity through data exclusivity, regulatory protections, and formulation patents.
Reimbursement and formulary integration	Strategic inclusion in insurance formularies sustains sales volume despite generics.
Pricing regulations	US courts and state agencies monitor pricing; price hikes face scrutiny, affecting revenue growth margins.
Upcoming Pipeline & Line Extensions	Janssen exploring once-daily formulations and combination therapies to reinforce market share.

---

What is the financial trajectory of CONCERTA?

Timeline & Projections	Key Indicators
2017-2022	Decline in branded sales (-10% CAGR) due to patent expiration and generic competition. Despite this, total methylphenidate market grew (~3-4% annually), with CONCERTA maintaining a significant share via differentiated profile.
2023-2027 forecast	Moderate recovery anticipated owing to new formulations, increased adult prescriptions, and market expansion in emerging regions. Revenue expected to stabilize around US$1.5–1.8 billion globally, with a compound annual growth rate (CAGR) of approx. 2-3%.
Factors influencing future revenue	- New formulation launches (e.g., once-daily maintenance versions) (Janssen, 2022). - Growing ADHD awareness in developing markets. - Increased adult treatment acceptance.
Risks to financial trajectory	- Intensified generic competition. - Regulatory hurdles for new formulations. - Pricing pressures due to healthcare reforms. - Shift toward non-stimulant or digital therapeutics.

---

How does CONCERTA compare with competitors’ financial strategies?

Aspect	CONCERTA (Janssen)	Vyvanse (Shire, now Takeda)	Strattera (Eli Lilly)
Pricing Strategy	Premium pricing maintained via brand loyalty	Maintains premium share through differentiated mechanism	Typically priced lower; non-stimulant alternative
Market Focus	Broad pediatric/adult ADHD	Focused on ADHD and binge-eating disorder	Non-stimulant niche market
Research & Development	Ongoing line extension research	Investment in novel formulations	Focus on alternative therapies

(Source: IQVIA, 2022; company filings)

---

Deep Dive: Market Segmentation and Revenue Breakdown

Region	Market Share (%)	Growth Rate (2022-2027)	Key Drivers
North America	60%	2-3%	Mature but expanding adult ADHD prescriptions
Europe	20%	3-4%	Growing awareness, reimbursement support
Asia-Pacific	10%	8-10%	Emerging demand, increasing diagnosis rates
Rest of World	10%	5-6%	Low current penetration, potential growth

---

What are the key policies affecting CONCERTA’s market future?

• FDA and EMA Regulations: Fast-track development for extended-release formulations could boost portfolio, while strict oversight can delay approvals.
• Pricing and Reimbursement Policies: Impact profitability, especially with increasing pressure for price controls.
• Intellectual Property Laws: Patent protections post-2017 limit generic encroachment temporarily but are finite.
• Market Access Strategies: Joint ventures and local manufacturing in emerging markets are vital for expansion.

---

How does the forecasted pipeline influence CONCERTA's outlook?

Pipeline Status	Expected Impact	Launch Timeline	Key Innovations
Once-Daily Formulations	Enhancement of adherence, competitive edge	2024-2026	Simplified dosing, improved compliance
Combination Therapies	Broader indications, personalized medicine	2025+	Potential to address comorbidities and enhance efficacy
Digital Therapeutics	Adjunct treatments, data collection	2023+	Integration with health devices for remote management

---

Conclusion: The Future Trajectory for CONCERTA

CONCERTA remains a pivotal product in the ADHD market, balancing mature brand strengths with emerging opportunities. While generic competition pressures margins, strategic innovation through formulation improvements and expanding indications—particularly in adult ADHD and emerging markets—can sustain growth. Careful navigation of regulatory policies and market access will be essential. Financially, Janssen’s investment in pipeline expansion and targeted marketing can elevate revenue levels to stabilize within $1.5–1.8 billion annually by 2027, with modest CAGR efforts maintaining its market presence.

---

Key Takeaways

• Market Position: CONCERTA retains significant market share despite patent expiry, driven by brand loyalty and formulary strategies.
• Growth Drivers: Increasing diagnosis rates, longer-lasting formulations, and regional expansion underpin future sales.
• Challenges: Erosion of exclusivity, generics, and pricing pressures necessitate innovation and market adaptation.
• Financial Outlook: Expected moderate growth with revenue stabilization around US$1.5–1.8 billion through 2027, supported by pipeline development.
• Strategic Focus: Emphasis on new formulations, expanded indications, and global access will be critical.

---

FAQs

Q1: How did patent expiry affect CONCERTA's market value?
A1: Patent expiration in 2017 led to increased generic competition, reducing brand sales by approximately 10% CAGR from 2017-2022. Nonetheless, brand loyalty and formulary access helped stabilize revenue.

Q2: What upcoming formulations or line extensions are expected for CONCERTA?
A2: Janssen is developing once-daily formulations and combination therapies aimed at improving adherence and expanding indications, with launches anticipated between 2024 and 2026.

Q3: How does regional market expansion influence CONCERTA's revenue?
A3: Emerging markets like Asia-Pacific are projected to see 8-10% annual growth, driven by increased ADHD diagnosis and healthcare investment, contributing to global revenue diversification.

Q4: What is the impact of non-stimulant treatments on CONCERTA's market share?
A4: Non-stimulant options like Strattera serve niche segments but generally do not threaten CONCERTA’s dominant stimulant position; however, they can divert some patients seeking alternatives.

Q5: How might healthcare policy reforms influence CONCERTA's future?
A5: Reforms favoring cost containment and price regulation could pressure margins. Conversely, policies supporting mental health awareness and access may bolster demand.

---

References

1. Centers for Disease Control and Prevention. (2022). Data & Statistics on ADHD.
2. IQVIA. (2022). U.S. Prescription Market Analysis.
3. Janssen Pharmaceuticals. (2022). Annual Report and Pipeline Overview.
4. U.S. Food & Drug Administration. (2020). Methylphenidate Extended-Release NDA Approvals.
5. EMA. (2021). ADHD Treatments Market Analysis.

---

Note: Data are estimates based on publicly available industry reports, academic research, and company disclosures up to 2023.